antithyroid drugs and/or I131 treatment do not provide an immediate therapeutic effect in improving patients' symptoms as it usually takes 4-6 weeks to achieve a euthyroid state. Since the introduction of percutaneous transvenous mitral commissurotomy (PTMC) by Inoue et al4) in 1984, this procedure has established itself as a safe and effective non-surgical therapeutic alternative for the treatment of selected patients with mitral stenosis. 5, 6) This report describes the usefulness of PTMC in patients who had severe mitral stenosis and hyperthyroidism. CASE 
REPORTS
From January 1987 to March 1995, 804 patients (229 males and 575 females) with severe mitral stenosis underwent PTMC with the Inoue balloon catheter technique4-6) in our institution. Thyroid function tests were performed only when indicated in this population and 8 females were documented to have hyperthyroidism. Two patients who had been treated for hyperthyroidism 18 and 24 months earlier, respectively, presented with heart failure despite being euthyroid. Severe mitral stenosis was then diagnosed and successful PTMC performed. Three other patients were diagnosed as having hyperthyroidism 16, 19 and 48 months after PTMC, respectively, because of a recurrence of dyspnea, palpitations and the development of other symptoms of hyperthyroidism. The additional three patients who were in a hyperthyroid state at the time of successful PTMC constitute the subjects of this report.
Of these three patients, one was still hyperthyroid despite having been treated for hyperthyroidism. The other two had unsuspected hyperthyroidism and had no previous history of thyroid disease, goiter or ophthalmopathy. These patients' clinical characteristics, hemodynamic data, and treatment outcomes are outlined in Table I . All patients had pliable, noncalcified mitral valves. There was no echocardiographic evidence of mitral restenosis (defined as loss of >50% of gain in the mitral valve area after PTMC) and they were in New York Heart Assocition (NYHA) Functional Class 1 at a follow-up period ranging from 60 to 84 months. The clinical histories of these three patients are detailed as follows. Case 1: A 51-year-old woman developed palpitations, orthopnea and paroxysmal nocturnal dyspnea one week prior to admission. Six months earlier, she was diagnosed elsewhere as having hyperthyroidism because of exertional dyspnea, palpitations and weight loss and commenced on antithyroid medications. She discontinued them 2 months later because of symptomatic improvement. Recurrent hyperthyroidism was diagnosed at admission. However, cardiac examination showed atrial fibrillation with a rapid ventricular rate of 140/minute and a loud first heart sound. There were no murmurs. Chest X-ray showed severe pulmonary venous congestion and an uncharacteristically mild cardiomegaly (a 
DISCUSSION
The coexistence of hyperthyroidism and rheumatic mitral stenosis is rare, and is most likely coincidental because the incidence of 1.4% (8 of 575 females) in our experience is similar to that (2% of the female and 0.2% of the male population) of hyperthyroidism diagnosed in the general population.7) Coexistence of hyperthyroidism and severe mitral stenosis may present a diagnostic challenge because both disorders may share a common presentation of cardiomegaly, atrial fibrillation, or congestive heart failure, and thus concomitant hyperthyroidism may be overlooked. This was exemplified in two of our three patients, in whom hyperthyroidism was detected only after successful PTMC when the dyspnea improved less than was expected and sinus tachycardia persisted despite excellent PTMC hemodynamic results. Therefore, when a patient's dyspnea is out of proportion to the severity of mitral stenosis (and if other more common causes of dyspnea, such as respiratory diseases and anemia have been excluded) and unexplained sinus tachycardia persists, hyperthyroidism should be suspected. Another clue for coexistence of hyperthyroidism is difficulty in controlling the ventricular rate of atrial fibrillation with digoxin.8) Once the coexistence of hyperthyroidism is suspected, its confirmation is readily made by thyroid function tests. However, in critically ill patients, such as those with severe congestive heart failure, the diagnosis of hyperthyroidism may be difficult because the thyroid hormone levels may provide falsely negative results. 9) There is a paucity of experience in the management of patients with hyperthyroidism and mitral stenosis because there have been only two such re-ported cases.1,2) The patient reported by Aoyagi et al1) underwent uneventful mitral valve replacement surgery after a euthyroid state had been attained after 9 months of antithyroid treatment with methylmercaptoimidazol. The other patient of Fujiwara et al2) was treated with antithyroid medication and subsequent subtotal thyroidectomy. The planned surgical mitral commissurotomy was not carried out because the patient became asymptomatic and cardiac catheterization performed after achievement of the euthyroid state showed the mitral stenosis to be mild.
The recent advent of PTMC4) has provided an additional therapeutic option in patients with coexisting hyperthyroidism and mitral stenosis. In our Patient 1 with intractable congestive heart failure, PTMC was performed based on the following reasons: 1) mitral valve surgery and anesthesia pose a significant morbidity and mortality in hyperthyroid patients,3) 2) antithyroid drugs and/or I131 treatment do not provide an immediate therapeutic effect in improving patients' symptoms as it usually takes 4-6 weeks to reach the euthyroid state, and 3) the patient had a pliable, noncalcified mitral valve suitable for PTMC.5,6) In Patients 2 and 3 in whom hyperthyroidism was unsuspected, PTMC was performed because both also had pliable, noncalcified mitral valves. In all 3 patients, PTMC resulted in an immediate hemodynamic and clinical improvement. However, complete clinical improvement occurred only when the euthyroid state was achieved with antithyroid treatment.
Although there have been reports of thyroid storm or hyperthyroidism induced by the use of contrast medium in patients with autonomous thyroid nodules,10-12) this occurrence in iodine-sufficient areas is rare, especially in patients without a prior history of thyroid disease.13) In Patients 2 and 3, hyperthyroidism was diagnosed 1 month after PTMC; it was probably preexistent and unsuspected rather than induced by the contrast medium administered during PTMC. Both patients had no goiter or a previous history of thyroid disease and reside in an iodine-sufficient area.14)
In conclusion, the present study suggests that PTMC is a safe and effective intervention modality in patients with coexisting hyperthyroidism and severe mitral stenosis. It may be considered a therapeutic option, especially for those patients with both hyperthyroidism and mitral stenosis who need urgent hemodynamic stabilization.
